Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $3.1 million.

  • Allogene Therapeutics' Depreciation & Amortization (CF) fell 3.43% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 9.72%. This contributed to the annual value of $13.6 million for FY2024, which is 3.95% down from last year.
  • Per Allogene Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $3.1 million for Q3 2025, which was down 0.29% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Depreciation & Amortization (CF) ranged from a high of $4.2 million in Q4 2021 and a low of $1.9 million during Q1 2021.
  • For the 3-year period, Allogene Therapeutics' Depreciation & Amortization (CF) averaged around $3.4 million, with its median value being $3.5 million (2023).
  • In the last 5 years, Allogene Therapeutics' Depreciation & Amortization (CF) soared by 130.04% in 2021 and then dropped by 27.68% in 2022.
  • Over the past 5 years, Allogene Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $4.2 million in 2021, then fell by 27.68% to $3.1 million in 2022, then increased by 13.36% to $3.5 million in 2023, then dropped by 7.04% to $3.2 million in 2024, then dropped by 3.43% to $3.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $3.1 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.1 million in Q1 2025.